Reports Q3 revenue $28.1M, consensus $27.2M. “The Q3 was marked by strong momentum from our commercial hematology-oncology portfolio driven by record TAVALISSE net product sales and growing REZLIDHIA awareness among leukemia treaters,” said Raul Rodriguez, Rigel’s president and CEO. “These strong net sales combined with our expense discipline have allowed us to make substantial progress on our plan to reach financial breakeven.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RIGL:
